Associated Papers
JAK/STAT in human diseases: a common axis in immunodeficiencies and hematological disorders.
Djidjik R et al.
Frontiers in Immunology, 2025
Insights into the role of JAK2-I724T variant in myeloproliferative neoplasms from a unique cohort of New Zealand patients.
Puli'uvea C et al.
Hematology (amsterdam, Netherlands), 2024
Diagnosis- and Prognosis-Related Gene Alterations in BCR::ABL1-Negative Myeloproliferative Neoplasms.
Morishita S et al.
International Journal of Molecular Sciences, 2023
Germline JAK2 E846D Substitution as the Cause of Erythrocytosis?
Maaziz N et al.
Genes, 2023
Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India.
Maddali M et al.
Hematology/oncology and Stem Cell Therapy, 2022
Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms.
Wiriyaukaradecha K et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2022
Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing.
Easwar A et al.
Life (basel, Switzerland), 2021
Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms.
Loscocco GG et al.
Cells, 2021
Myelofibrosis biology and contemporary management.
Gangat N et al.
British Journal of Haematology, 2020
Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data.
Loscocco GG et al.
Oncotargets and Therapy, 2020
Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.
Zuo Z et al.
Current Hematologic Malignancy Reports, 2019
Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.
Vu HA et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2019
Mayo CALR mutation type classification guide using alpha helix propensity.
Lasho TL et al.
American Journal of Hematology, 2018
Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature.
Zhou A et al.
Current Hematologic Malignancy Reports, 2017
Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology.
Guglielmelli P et al.
Leukemia Research, 2017
Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies.
Finazzi MC et al.
Expert Review of Hematology, 2017
Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients.
Yoo EH et al.
Journal of Clinical Laboratory Analysis, 2016
A novel calreticulin mutation in a patient with myeloproliferative neoplasm.
Hill AM et al.
Annals of Hematology, 2016
Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
Kang MG et al.
Oncotarget, 2016
Genetic-pathologic characterization of myeloproliferative neoplasms.
Kim Y et al.
Experimental & Molecular Medicine, 2016
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.
Pietra D et al.
Leukemia, 2016
A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin-embedded bone marrow biopsies.
Stein H et al.
Leukemia, 2016
Low neutrophil alkaline phosphatase score is a new aspect of calreticulin-mutated myeloproliferative neoplasms.
Kondo T et al.
Springerplus, 2016
The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.
Lin Y et al.
American Journal of Clinical Pathology, 2015
Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS et al.
Annals of Laboratory Medicine, 2015
Calreticulin mutations and long-term survival in essential thrombocythemia.
Tefferi A et al.
Leukemia, 2014
Low frequency of calreticulin mutations in MDS patients.
Heuser M et al.
Leukemia, 2014
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
Rumi E et al.
Blood, 2014